Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2011-03-01
2011-03-01
Chernyshev, Olga N (Department: 1649)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C435S326000, C435S320100, C435S252300, C435S254110, C536S023500
Reexamination Certificate
active
07897725
ABSTRACT:
The invention provides novel Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 proteins, the invention further provides isolated Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 fusion proteins, antigenic peptides and anti-Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 antibodies. The invention also provides Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 and A259 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which a Delta3, FTHMA-070, Tango85, Tango77, SPOIL, NEOKINE, Tango129 or A259 gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided.
REFERENCES:
patent: 5011912 (1991-04-01), Hopp et al.
patent: 6121045 (2000-09-01), McCarthy et al.
patent: 0325474 (1989-07-01), None
patent: 0861894 (1998-09-01), None
patent: 0972041 (2000-01-01), None
patent: 1240697 (1989-09-01), None
patent: WO-92/19734 (1992-11-01), None
patent: WO-97/01571 (1997-01-01), None
patent: WO-97/19172 (1997-05-01), None
patent: WO-98/45434 (1998-10-01), None
patent: WO-98/51799 (1998-11-01), None
Artavanis-Tsakonas et al., Notch signaling. Science, 268: 225-32 (1995).
Benedito et al., Loss of notice signaling induced by DII4 causrs arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev. Biol., 8: 117-21 (2008).
U.S. Appl. No. 08/832,633, McCarthy et al.
Bettenhausen et al., Genbank Accession No. X80903, Sep. 29, 1995.
Bettenhausen et al., Transient and restricted expression during mouse embryogenesis of DII1, a murine gene closely related to Drosophila Delta,Development, 121: 2407-18 (1995).
Chitnis et al., Primary neurogenesis in Xenopus embryos regulated by a homologue of the Drosophila neurogenic gene Delta,Nature, 375: 761-6 (1995).
Clark et al., Genbank Accession No. AAQ89253, dated Oct. 3, 2003.
Disibio et al., Genbank Accession No. U78889, Dec. 3, 1996.
Dornseifer et al., Genbank Accession No. Y11760, Apr. 18, 2005.
Dornseifer et al., Overexpression of zebrafish homolog of the Drosophila neurogenic gene Delta perturbs differentiation of primary neurons and somite development,Mech. Dev. 63: 159 (1997).
Dorsch et al. Ectopic expression of Delta4 impairs hematopoietic development and leads to lymphoproliferative disease,Blood, 100(6):2046-55 (2002).
Duarte et al., Dosage-sensitive requirement for mouse DII4 in artery development. Genes Dev. 18: 2474-8 (2004).
Dunwoodie et al., Mouse DII3: A novel divergent delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development, 124: 3065-76 (1997).
Ellisen et al., TAN-1, the human homolog of the drosophila notch gene, is broken by chromosomal translocations in T lymphoclastic neoplasms. Cell, 66: 649-61 (1991).
Harbe de Angelis et al., Maintenance of somite borders in mice requires the Delta homologue DII1. Nature, 386: 717-21 (1997).
Harlow et al., Antibodies: A Laboratory Manual (1988).
Henrique et al., Expression of a Delta homologue in prospective neurons in the chick,Nature, 375: 787-90 (1995).
Henrique et al., Genbank Accession No. L42229, Jul. 17, 1995.
Henrique et al., Genbank Accession No. GGU26590, Aug. 9, 1995.
Hoey et al., DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell, 5: 168-77 (2009).
Information regarding commercially available delta (C-20): SC-8155 polyclonal antibody supplied by Santa Cruz Biotechnology, Inc., Jun. 2, 2009.
Ja et al., Notch signaling in development and disease. Clin. Genet. 64: 461-72 (2003).
Jaleco et al., Differential effects of notch ligands delta-1 and jagged-1 in human lymphoid differentiation. J. Exp. Med. 194(7): 991-1001 (2001).
Jen et al., Genbank Accession No. XLU70843, Nov. 30, 1996.
Jen et al., The notice ligand, X-Delta-2, mediates segmentation of the paraxial mesoderm in Xenopus embryos,Development, 124: 1169-78 (1997).
Karanu et al., Human homologues of Delta-1 and Delta-4 function as mitogenic regulators of primitive human hematopoietic cells. Blood,97(7): 1960-7 (2001).
McCarthy et al., GenSeq Accession No. AAV68523, Feb. 16, 1999.
McCarthy et al., GenSeq Database Entry No. AAW80813, Feb. 16, 1999.
Milner et al., A human homologue of the drosophila development gene, notch, is expressed in CD34+ hematopoietic precursors. Blood, 83: 2057-62 (1994).
Noguera-Troise et al., Blockade of DII4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 444: 1032-7 (2006).
Nye et al., Vertebrate ligands for notch, Dev. Signaling, 5(9): 966-9 (1995).
Rebay et al., Specific EGF repeats of notch mediate interactions with delta and serrate: Implications for notch as a multifunctional receptor. Cell, 67: 697-9 (1991).
Ridgway et al., Inhibition of DII4 signalling inhibits tumour growth by deregulating angiogenesis. Nature, 444: 1083-7 (2006).
Rubio-Aliaga et al., DII1 haploinsufficiency in adult mice leads to a complex phenotype affecting metabolic and immunological processes. PLoS One, 4: e6054 (2009).
Sakano et al., GenSeq Accession No. AAW94496, Apr. 22, 1999.
Sakano et al., Genbank Accession No. AAX16297, Apr. 22, 1999.
Sakano et al., Genbank Accession No. BAB16085, dated Oct. 3, 2000.
Shutter et al., DII4, a novel notch ligand expressed in arterial endothelium,Gene Dev. 14: 1313-18 (2000).
Shutter et al., Genbank Access No. AAF76427, dated Jun. 16, 2000.
Singh et al., Expression of notch receptors, notch ligand, and fringe genes in hematopoiesis. Exp. Hematol. 28: 527-34 (2000).
Smith et al., Blocking of HIV-1 infectivity by a soluble, secreted form of CD4 antigen.Science, 238: 1704-7 (1987).
Strausberg et al., Genbank Accession No. AAI06951, dated Oct. 4, 2006.
Suzuki et al., Notch signaling in hematopoietic stem cells,Int. J. Hematol. 82: 285-94 (2005).
Taga et al., Interleukin-6 triggers the association of its receptor with a possible signal transducer, gq130.Cell, 58: 573-81 (1989).
Vassin et al., The neurogenic gene Delta of Drosophila melanogaster is expressed in neurogenic territories and encodes a putative transmembrane protein with EGF-like repeats,EMBO J. 6(11): 3431-40 (1987).
Vassin et al., Genbank Accession No. X06289, dated Apr. 18, 2005.
Venter et al., Genbank Accession No. EAW92466, dated Dec. 18, 2006.
Weber et al., Medium-scale ligand-affinity purification of two soluble forms of human interleukin-2 receptor.J. Chromatogr. 431: 55-63 (1988).
Yamasaki et al., Cloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptor.Science, 241: 825-8 (1988).
Yoneya et al., Genbank Accession No. BAB18581, dated Nov. 29, 2000.
Notice of Opposition to European Patent 0972041 filed by Regeneron Pharmaceuticals, Inc., European Patent Office, Jul. 10, 2007.
Notice of Opposition to European Patent 0972041 filed by Anita Thrikettle, European Patent Office, Jul. 11, 2007.
Notice of Opposition to European Patent 1004669 filed by Regeneron Pharmaceuticals, Inc., European Patent Office, Jan. 16, 2008.
Notice of Opposition to European Patent 1004669 filed by Millennium Pharmaceuticals, Inc., European Patent Office, Jan. 17, 2008.
Notice of Opposition to European Patent 1004669 filed by Strawman Limited, European Patent Office, Jan. 17, 2008.
Notice of Opposition to European Patent 1004669 filed by Dr. Albrecht Dehmel, European Patent Office, Feb. 1, 2008.
Yan et al., “Chronic DLL4 blockade induces vascular neoplasms”, Nature, 463:E6-E7 (Feb. 2010).
Gearing David P.
McCarthy Sean A.
Chernyshev Olga N
Marshall & Gerstein & Borun LLP
Millenium Pharmaceuticals
LandOfFree
Delta3 (tango24) protein and nucleic acid molecules and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delta3 (tango24) protein and nucleic acid molecules and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delta3 (tango24) protein and nucleic acid molecules and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2644058